JP7039554B2 - 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート - Google Patents

抗ｐｓｍａ抗体、その使用及びそのコンジュゲート Download PDF

Info

Publication number
JP7039554B2
JP7039554B2 JP2019502698A JP2019502698A JP7039554B2 JP 7039554 B2 JP7039554 B2 JP 7039554B2 JP 2019502698 A JP2019502698 A JP 2019502698A JP 2019502698 A JP2019502698 A JP 2019502698A JP 7039554 B2 JP7039554 B2 JP 7039554B2
Authority
JP
Japan
Prior art keywords
antibody
group
antigen
binding portion
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019502698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535232A5 (https=
JP2019535232A (ja
Inventor
ロバート・ジョージ・エドワード・ホルゲート
アロン・ロバート・ハーン
Original Assignee
ポリセリックス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポリセリックス・リミテッド filed Critical ポリセリックス・リミテッド
Publication of JP2019535232A publication Critical patent/JP2019535232A/ja
Publication of JP2019535232A5 publication Critical patent/JP2019535232A5/ja
Priority to JP2022035222A priority Critical patent/JP7486538B2/ja
Application granted granted Critical
Publication of JP7039554B2 publication Critical patent/JP7039554B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019502698A 2016-08-18 2017-08-18 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート Active JP7039554B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022035222A JP7486538B2 (ja) 2016-08-18 2022-03-08 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1614162.4 2016-08-18
GBGB1614162.4A GB201614162D0 (en) 2016-08-18 2016-08-18 Antibodies, uses thereof and conjugates thereof
PCT/GB2017/052448 WO2018033749A1 (en) 2016-08-18 2017-08-18 Anti-psma antibodies, uses thereof and conjugates thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022035222A Division JP7486538B2 (ja) 2016-08-18 2022-03-08 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート

Publications (3)

Publication Number Publication Date
JP2019535232A JP2019535232A (ja) 2019-12-12
JP2019535232A5 JP2019535232A5 (https=) 2020-09-17
JP7039554B2 true JP7039554B2 (ja) 2022-03-22

Family

ID=57045541

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019502698A Active JP7039554B2 (ja) 2016-08-18 2017-08-18 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート
JP2022035222A Active JP7486538B2 (ja) 2016-08-18 2022-03-08 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022035222A Active JP7486538B2 (ja) 2016-08-18 2022-03-08 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート

Country Status (7)

Country Link
US (1) US11059903B2 (https=)
EP (2) EP3500595B1 (https=)
JP (2) JP7039554B2 (https=)
CN (1) CN110049999B (https=)
ES (1) ES2983492T3 (https=)
GB (1) GB201614162D0 (https=)
WO (1) WO2018033749A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
MX2020009272A (es) 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
MX2020010104A (es) * 2018-03-29 2020-11-06 Ambrx Inc Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
EP3994177A4 (en) * 2019-07-02 2023-09-20 Telix International Pty Ltd PSMA-BINDING ANTIBODIES WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR
CN114729059A (zh) 2019-09-11 2022-07-08 宾夕法尼亚大学董事会 包含前列腺干细胞抗原(psca)嵌合抗原受体(cars)的组合物和方法
EP4063387A4 (en) * 2019-11-22 2023-08-02 Nantong Yichen Biopharma. Co. Ltd. PSMA ANTIBODIES AND ITS USE
CN110922486B (zh) * 2020-02-18 2020-05-22 和铂医药(上海)有限责任公司 一种分离的结合抗原psma的蛋白及其用途
CN120813607A (zh) * 2023-02-28 2025-10-17 卫材R&D管理有限公司 抗psma抗体、缀合物和使用方法
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
CN116196428B (zh) * 2023-04-04 2025-04-04 上海愿智生物技术有限公司 一种药物组合物及其应用
CN116271081A (zh) * 2023-04-04 2023-06-23 上海愿智生物技术有限公司 一种抗体偶联药物yc1605及其药物组合物和应用
WO2026044149A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthesis of drug-linker combinations for antibody-drug conjugates

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009017823A2 (en) 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health A fold-back diabody diphtheria toxin immunotoxin and methods of use
WO2014064423A1 (en) 2012-10-24 2014-05-01 Polytherics Limited Drug-protein conjugates
JP2015078168A (ja) 2013-10-18 2015-04-23 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａリガンドコンジュゲートによる併用療法
WO2015177360A1 (en) 2014-05-22 2015-11-26 Synthon Biopharmaceuticals B.V. Site-specific conjugation of linker drugs to antibodies and resulting adcs
WO2016063006A1 (en) 2014-10-24 2016-04-28 Polytherics Limited Conjugates and conjugating reagents

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
DE69737346T2 (de) 1996-07-24 2007-10-31 Koninklijke Philips Electronics N.V. Verbesserungen an optisch lesbaren platten und plattenaufzeichnungsgerät
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP5355839B2 (ja) 2001-10-23 2013-11-27 ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． Ｐｓｍａ抗体およびタンパク質マルチマー
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
US20040136998A1 (en) 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
CN101160324B (zh) * 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
JP2008529556A (ja) 2005-02-18 2008-08-07 メダレックス， インク． 前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体
CN101820920B (zh) 2007-10-09 2014-08-06 宝力泰锐克斯有限公司 新的缀合蛋白质和肽
CN101891818B (zh) * 2009-01-16 2012-07-25 中国人民解放军第四军医大学 抗人前列腺特异性膜抗原胞外区单链抗体及其应用
EP2403538B1 (en) 2009-03-04 2017-10-04 Polytherics Limited Conjugated proteins and peptides
EP2861261A2 (en) * 2012-06-19 2015-04-22 Polytherics Limited Process for preparation of antibody conjugates and antibody conjugates
NO2789793T3 (https=) 2012-10-24 2018-01-27
IL311390A (en) * 2013-03-15 2024-05-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
US20150110814A1 (en) * 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
EP3218009B1 (en) 2014-10-14 2021-04-07 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
MX2020009272A (es) * 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009017823A2 (en) 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health A fold-back diabody diphtheria toxin immunotoxin and methods of use
WO2014064423A1 (en) 2012-10-24 2014-05-01 Polytherics Limited Drug-protein conjugates
JP2015078168A (ja) 2013-10-18 2015-04-23 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａリガンドコンジュゲートによる併用療法
WO2015177360A1 (en) 2014-05-22 2015-11-26 Synthon Biopharmaceuticals B.V. Site-specific conjugation of linker drugs to antibodies and resulting adcs
WO2016063006A1 (en) 2014-10-24 2016-04-28 Polytherics Limited Conjugates and conjugating reagents

Also Published As

Publication number Publication date
EP3500595B1 (en) 2024-05-01
GB201614162D0 (en) 2016-10-05
ES2983492T3 (es) 2024-10-23
JP2022084715A (ja) 2022-06-07
US11059903B2 (en) 2021-07-13
JP7486538B2 (ja) 2024-05-17
US20190300623A1 (en) 2019-10-03
EP4403226A3 (en) 2024-10-16
EP3500595A1 (en) 2019-06-26
CN110049999A (zh) 2019-07-23
WO2018033749A1 (en) 2018-02-22
CN110049999B (zh) 2023-12-19
EP4403226A2 (en) 2024-07-24
JP2019535232A (ja) 2019-12-12

Similar Documents

Publication Publication Date Title
JP7486538B2 (ja) 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート
JP7564176B2 (ja) 抗体、その使用及びそのコンジュゲート
JP7016975B2 (ja) ナノ粒子イムノコンジュゲート
JP6257669B2 (ja) ヒト前立腺特異的膜抗原（ｐｓｍａ）をターゲッティングするｊ５９１ミニボディおよびｃｙｓダイアボディならびにこれらを使用するための方法
JP5739880B2 (ja) ＩｇＧ結合のための部位を同定するための方法
AU2018296644B2 (en) Novel anti-human CEACAM5 antibody Fab fragment
KR20220083785A (ko) 인간화 항체 및 그 사용 방법
CA3068691C (en) Anti-human ceacam5 antibody fab fragment
CN120112554A (zh) 整合素α10抗体药物偶联物
TW202346338A (zh) pH依賴性抗硫酸化醣胺聚醣抗體及抗體藥物複合體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220309

R150 Certificate of patent or registration of utility model

Ref document number: 7039554

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250